Evidence map›Paper›PMID 30413718›Full record

ArticleNature communications2018

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Yunhua Liu, Jiangsheng Xu, Hyun Ho Choi, Cecil Han, Yuanzhang Fang, Yujing Li, Kevin Van der Jeught, Hanchen Xu, Lu Zhang, Michael Frieden and 12 more

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. SEC61G assistsProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Yunhua LiuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.ORCID http://orcid.org/0000-0003-2017-3059
Jiangsheng XuDepartment of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Hyun Ho ChoiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Cecil HanDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yuanzhang FangDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Yujing LiDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Kevin Van der JeughtDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.ORCID http://orcid.org/0000-0002-4626-2343
Hanchen XuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Lu ZhangDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Michael FriedenDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Lifei WangDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Haniyeh EyvaniDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Yifan SunDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Gang ZhaoDepartment of Electronic Science and Technology, School of Information Science and Technology, University of Science and Technology of China, 230027, Hefei, China.ORCID http://orcid.org/0000-0002-0201-1825
Yuntian ZhangDepartment of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Sheng LiuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Jun WanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Cheng HuangDrug Discovery Laboratory, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Guang JiInstitute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 200032, Shanghai, China.ORCID http://orcid.org/0000-0003-0842-3676
Xiongbin LuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. xiolu@iu.edu.
Xiaoming HeDepartment of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA. shawnhe@umd.edu.ORCID http://orcid.org/0000-0003-0125-6086
Xinna ZhangDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. xz48@iu.edu.
The University of Texas MD Anderson Cancer Center · USIndiana University School of MedicineIndiana University Health · USShanghai University of Traditional Chinese Medicine · CNThe Ohio State University · USUniversity of Maryland, Baltimore · USUniversity of Science and Technology of China · CN

Funding

Targeting Human Cancers with Hemizygous Deletion of TP53R01CA203737 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, XIONGBIN, SCHNEIDER, BRYAN PAUL · 2016 to 2023
$3.4M
Nanotechnology enabled targeting of p53 deficiency in human cancerR01CA206366 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING, LU, XIONGBIN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA203737NCI NIH HHS R01 CA206366
6 · The paper itself

Abstract

Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majority of the WIP1-containing 17q23 amplicons. The 17q23 amplification results in aberrant expression of WIP1 and miR-21, which not only promotes breast tumorigenesis, but also leads to resistance to anti-HER2 therapies. Inhibiting WIP1 and miR-21 selectively inhibits the proliferation, survival and tumorigenic potential of the HER2+ breast cancer cells harboring 17q23 amplification. To overcome the resistance of trastuzumab-based therapies in vivo, we develop pH-sensitive nanoparticles for specific co-delivery of the WIP1 and miR-21 inhibitors into HER2+ breast tumors, leading to a profound reduction of tumor growth. These results demonstrate the great potential of the combined treatment of WIP1 and miR-21 inhibitors for the trastuzumab-resistant HER2+ breast cancers.

Indexed as

AnimalsAntineoplastic AgentsBreast NeoplasmsCarcinogenesisCell DeathCell Line, TumorCell ProliferationChromosomes, Human, Pair 17DEAD-box RNA HelicasesDrug Delivery SystemsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene AmplificationHumansMiceAntineoplastic AgentsDdx5 protein, humanDEAD-box RNA HelicasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsMIRN21 microRNA, humanPPM1D protein, humanProtein Phosphatase 2CTrastuzumab

Identifiers

PMID30413718
PMCPMC6226492
OpenAlexW2900228330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.